



1647
\$

Please type a plus sign (+) inside this box → +

PTO/SB/21 (08-00)

Approval for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/691,343	
	Filing Date	Oct 18, 2000	
	First Named Inventor	Turner, Jr., C. Alexander	
	Group Art Unit	1647	
	Examiner Name	R. Deberry	
Total Number of Pages in This Submission	43	Attorney Docket Number	LEX-0070-USA

RECEIVED

MAR 17 2003

TECH CENTER 600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request (Original & Copy) <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - Return Postcard - Exhibits A - F
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Lexicon Genetics Incorporated Lance K. Ishimoto Reg. No. 41,866
Signature	<i>Lance K. Ishimoto by David W. Hoyer</i> DAVID W. HOYER 24231 REG. NO. 41,071 PATENT TRADEMARK OFFICE
Date	March 6, 2003

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Arlington, VA 22202 on this date: March 6, 2003			
Typed or printed name	Michelle Klein		
Signature	<i>Michelle Klein</i>	Date	March 6, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

B/13
1PP
3/24/03

Applicant(s): Turner Jr. *et al.* Group Art Unit: 1647
Application No.: 09/691,343 Examiner: R. DeBerry
Filed: 10/18/2000 Atty. Docket No.: LEX-0070-USA
Title: Novel Human Proteins and Polynucleotides
Encoding the Same

AMENDMENT AND RESPONSE TO OFFICE ACTION
DATED NOVEMBER 6, 2002

RECEIVED

Assistant Commissioner for Patents
Arlington, VA 22202

MAR 17 2003
TECH CENTER 1600/2900

Sir:

The Applicants acknowledge the receipt of the Office Action ("the Action") mailed on November 6, 2002 (Paper No. 11), which has been carefully reviewed and studied. The Examiner is respectfully requested to enter the following amendments. Reexamination and reconsideration of the application is requested in view of the following amendments and remarks. In order to facilitate the Examiner's evaluation of the application, Applicants have attempted to address the rejections in Paper No. 11 in the same order in which they were originally raised.

A Petition for an Extension of Time of one month to and including March 6, 2003, and authorization to deduct the fee as required under 37 C.F.R. § 1.17(a)(1) from Applicants' representatives Deposit Account are included. The response is thus timely filed. Applicants believe no fees in addition to the fee for the extension of time are due in connection with this response. However, the Commissioner is authorized to charge any additionally required fees or credit any overpayment to Deposit Account No. 50-0892.

AMENDMENT

In the claims:

Please amend claim 5 so that the text of the amended claim reads as follows:

5. (Twice Amended) An isolated nucleic acid molecule comprising a nucleotide sequence that:

B1



24231

PATENT TRADEMARK OFFICE